FEELM
27.5.2022 13:40:10 CEST | Business Wire | Press release
FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/
As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disposable category is expected to reach USD2.72 billion, making up over 43% of closed system vaping products.
However, almost all the existing disposable vapes are equipped with cotton coil, which produces relatively large aerosol particles, leading to inefficient deposition of inhaled particles in the lungs, hence low nicotine delivery and satisfaction, as well as harshness in throat. Soft cotton coils are unable to form a stable structure, hence a high leakage rate and unpleasant burnt taste. Uneven heating of cotton coils could also cause a weak flavor consistency, so that vaping experience will fade gradually. Moreover, the selling points of most disposable vapes currently focus on large-mouth puff count, or rather, the huge number of puffs that the disposable will provide.
To address the three pain points, FEELM unveils the world's first ceramic coil disposable pod solution, FEELM Max is to disposable vapes what internal combustion engine is to airplanes, automobiles, ships, submarines, and trains. It aims to provide the next generation of disposable vapes with a stronger, more reliable and efficient atomization “engine”. Just like internal combustion engine, which features high thermal efficiency, light weight, compact size and maneuverability, marking the coming of the second industrial revolution; FEELM Max is expected to lead another ceramic coil revolution in the global vaping industry, since the launch of FEELM Air in January 2022.
This revolutionary vaping solution has largely improved e-liquid utilization by virtue of a cotton-free structure and microporous ceramic coil. Therefore, its puff number is increased by 25% with the same e-liquid volume, compared with traditional cotton coil disposable vapes. Besides, it can provide an unprecedented silky-smooth vaping experience, thanks to the ceramic coil, which generates smaller vaporized aerosol particles, thereby minimizing residue in throat. In contrast to cotton coil disposable vapes, the smoothness is improved also by 30%. This innovation also boasts extraordinary flavor consistency of over 95%, since ceramic coil can guarantee constant vapor production, so as to bring the same strong and great taste till the last puff.
In addition to the three major benefits, FEELM Max also features 46% increased overall harm reduction performance compared with cotton coil vapes, and ultra-low vaping leakage rate of less than 0.03%, empowered by Maze Leakage-proof Technology. The smaller vaporized aerosol particles generated by FEELM ceramic coil tend to deposit more in the lung, bringing greater and faster satisfaction. Meanwhile, FEELM's patented Flavor-Lock technology can bring tailored flavor release with terraced temperature zones.
In early 2022, FEELM Max has been adopted by a specialist vape retailer in the UK. In partnership with FEELM, this retailer has introduced an ultra-slim disposable product equipped with FEELM ceramic coil. Built to be lightweight and compact, this product is designed specifically for smoking cessation. In April, the two partners participated in VApril 2022, the world’s largest vaping awareness campaign to give away disposable vapes to adult smokers seeking to switch in London and Manchester.
At Vaper Expo UK 2022, FEELM has also showcased other industry-leading, pioneering disposable vaping solutions, for example, eco-friendly non-nicotine disposable e-cigarette and anti-dust mouthpiece hygienic e-cigarette. These two have been awarded Red Dot Awards for Product Design 2022 for their green product concepts and avant-garde design. Unlike traditional disposable e-cigarettes made of plastic, the external structure of eco-friendly non-nicotine disposable e-cigarette is composed of recyclable and reusable paper and aluminum foil while anti-dust mouthpiece hygienic e-cigarette features a twist nozzle to prevent the contact of mouthpiece with something unclean, with the product concept originated from lipsticks.
Another award-winning solution displayed at the event is FEELM Air, the world’s thinnest ceramic coil vape pod solution. In collaboration with its global clients, FEELM has demonstrated a series of vaping products of regional leading brands that adopt FEELM Air solution. Moreover, it will announce the 2022 timeline of commercial launch of FEELM Air on a global scale afterwards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
